PTEN and cancer: These pathways are hyperactive in the vast majority of cancers, mainly due to activating mutations of RAS, BRAF and PI3K or loss-of-function mutations of the tumor suppressor PTEN, which are among the most common genetic perturbations in cancer (Kandoth et al., 2013).